Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4736556 | 1.00 | TSHR (0.31) | TSHRALDH1A1HSD17B10 | |
| SCHEMBL17866508 | 0.86 | TSHR (0.31) | TSHRALDH1A1HSD17B10 | |
| SCHEMBL4787362 | 0.82 | SMN1; SMN2 (0.37) | TSHRALDH1A1 | |
| SCHEMBL1866475 | 0.80 | TSHR (0.43) | TSHRALDH1A1HSD17B10 | |
| SCHEMBL580557 | 0.80 | TSHR (0.43) | TSHRALDH1A1HSD17B10 | |
| SCHEMBL17617132 | 0.80 | TSHR (0.43) | TSHRALDH1A1HSD17B10 | |
| SCHEMBL13541326 | 0.80 | TSHR (0.43) | TSHRALDH1A1HSD17B10 | |
| SCHEMBL2978632 | 0.78 | MAPT (0.42) | TSHRALDH1A1HSD17B10 | |
| SCHEMBL25875641 | 0.78 | CTSK (0.34) | TSHRALDH1A1HSD17B10 | |
| SCHEMBL4439936 | 0.78 | MAPT (0.42) | TSHRALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324273-B2 | Catechol protected levodopa diester prodrugs, compositions, and methods of use | XENOPORT, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20080171789-A1 | Catechol protected levodopa diester prodrugs, compositions, and methods of use | XENOPORT, INC. | 2008-07-17 | — | — | US | disclosed |
| WO-2008079387-A1 | CATECHOL PROTECTED LEVODOPA DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE | XENOPORT, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171789-A1 | Catechol protected levodopa diester prodrugs, compositions, and methods of use | COMT, PARK7, DDT | TSHR 3809/4885ALDH1A1 636/4885HSD17B10 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.